Key result
Higher serum TMAO levels linked to ~1% higher odds of aortic stiffness in hemodialysis patients.
Why the study?
TMAO predicts major adverse cardiovascular events and aortic stiffness is independently linked to CV morbidity and mortality, but their association in hemodialysis patients required evaluation.
Are higher serum TMAO levels associated with increased aortic stiffness in patients on maintenance hemodialysis?
Cross-Sectional (n=115)
No
Are higher serum TMAO levels associated with increased aortic stiffness in patients on maintenance hemodialysis?
Serum TMAO is an independent predictor of aortic stiffness in hemodialysis patients, highlighting a potential gut-derived biomarker for uremic vascular aging.
Answers are grounded in this paper and cite their sources.
TMAO associated with aortic stiffness in hemodialysis; leaves open causality, prediction, and therapeutic targeting.
Trimethylamine N-oxide (TMAO) is a biomarker that is effective in predicting major adverse cardiovascular (CV) events. Age-related vascular problems are significantly affected by aortic stiffness (AS), which is independently linked to CV morbidity and mortality. This study aimed to determine the association between serum TMAO levels and carotid–femoral pulse wave velocity (cfPWV) in patients receiving hemodialysis (HD) therapy. In total, 115 patients with HD were enrolled in this study. The AS group included patients whose cfPWV was >10 m/s. Using high-performance liquid chromatography and mass spectrometry, the levels of serum TMAO were measured. The AS group included 42 (36.5%) patients, and compared with the non-AS group, the rates of diabetes, hypertension, older age, systolic blood pressure, serum glucose, and TMAO levels were high. In the multivariate logistic regression analysis, serum TMAO and age were independently linked with AS after correcting for the factors significantly associated with AS. Following multivariate stepwise linear regression analysis, serum TMAO in these individuals was found to be strongly correlated with cfPWV values (p < 0.001). In patients on chronic HD, serum TMAO level is an independent measure of AS and strongly correlated with cfPWV.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2023) conducted a cross-sectional in Maintenance hemodialysis (kidney failure) (n=115). Serum trimethylamine N-oxide (TMAO) level was evaluated on Aortic stiffness defined by carotid–femoral pulse wave velocity >10 m/s (OR 1.010, 95% CI 1.003-1.017, p=0.003). Higher serum TMAO levels were independently associated with the presence of aortic stiffness in patients on maintenance hemodialysis (OR 1.010).
Synapse has enriched 10 related papers. Consider them for comparative context: